Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Earnings Results, Beats Estimates By $0.09 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) issued its earnings results on Thursday. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.09, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• ALTITUDE-AD readout late 2026 — Acumen expects full efficacy and safety results from its phase II sabirnetug study this year, which the company says will inform its late‑stage development strategy and the broader Aβ‑oligomer hypothesis in AD.
• Preclinical EBD progress and funding — non‑human primate data showed 14–40‑fold higher brain levels for EBD candidates versus native antibody, the profiles exceeded targets, and a recent $35.75 million private placement was raised to advance the program toward an IND targeted in mid‑2027.
• Supportive Phase Ib biomarker signals — in INTERCEPT‑AD sabirnetug produced early CSF improvements (notably phospho‑tau‑181 and neurogranin) after three doses, which management views as supportive for potential phase II efficacy.
• Limited near‑term cash runway and high 2025 losses — year‑end cash and marketable securities of $116.9 million are expected to fund operations only into early 2027, and the company reported a $121.3 million net loss in 2025, implying additional financing will likely be needed to fully execute longer‑term plans.

Acumen Pharmaceuticals Stock Down 5.6%

Acumen Pharmaceuticals stock opened at $2.48 on Thursday. The company has a quick ratio of 6.02, a current ratio of 6.02 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $150.33 million, a P/E ratio of -1.10 and a beta of 0.21. The firm has a 50 day moving average price of $2.68 and a 200-day moving average price of $2.15. Acumen Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $3.60.

Insider Buying and Selling

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 37,755 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $1.99, for a total transaction of $75,132.45. Following the completion of the transaction, the chief executive officer directly owned 619,982 shares of the company’s stock, valued at approximately $1,233,764.18. This represents a 5.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 149,818 shares of company stock valued at $285,057 in the last quarter. 9.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. bought a new stake in Acumen Pharmaceuticals in the 3rd quarter valued at about $27,000. Marshall Wace LLP bought a new position in shares of Acumen Pharmaceuticals during the fourth quarter valued at about $44,000. OMERS ADMINISTRATION Corp purchased a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $47,000. Marex Group plc bought a new position in Acumen Pharmaceuticals during the 2nd quarter valued at approximately $39,000. Finally, AQR Capital Management LLC purchased a new stake in Acumen Pharmaceuticals in the 1st quarter worth approximately $46,000. Institutional investors own 71.01% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ABOS shares. Wall Street Zen downgraded Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday, January 9th. Finally, BTIG Research upped their target price on shares of Acumen Pharmaceuticals from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.